Blood flow can be immediately restored following ultrasonographically guided hyaluronidase injections into deposits responsible for the occlusion

Odds of being satisfied with treatment increased for patients primarily treated by a dermatologist

Findings show dose-response relationship, with higher risk tied to more severe atopic dermatitis

No increase in adverse events seen with continued maintenance and open-label treatment

Cumulative probability of being relapse-free at 24 months after withdrawal was 4.7 percent

Among those with atopic dermatitis, smoking and male sex were significantly associated with higher risk for new-onset migraine

Twelve instruments were selected to measure outcomes in the value-based outcome set, which were reported by patients and providers

Presence of RLS associated with significantly more severe psoriasis and more severe systemic inflammation

Algorithm is 92 percent accurate and predicted scores with errors comparable to annotators

Following induction dose, maintenance dose of 125 or 250 mg every eight weeks from weeks 16 to 52 was comparably safe and efficacious

Companies announced that the vaccine performed well in a small study of patients who had the cancer surgically removed

Significantly longer progression-free survival seen with infusion of tumor-infiltrating lymphocytes versus ipilimumab

More patients in 5-FU versus cryotherapy group had complete response to treatment, and median VAS was lower

Patient age, baseline body weight, disease severity measured by PASI, Investigator's Global Assessment predict response to guselkumab

Significant reduction seen in mortality rate from 2013 to 2017, after the introduction of new treatments in 2011 (most after 2013)

However, scar located on lower lid mid subunit perpendicular to facial tension lines was rated as less attractive

Potential benefit seen for multiple supplements, including omegas 3 and 6 with antioxidants, zinc, pumpkin seed oil

Significant differences seen from placebo in percentage change from baseline in the Facial-Vitiligo Area Scoring Index for 50, 30 mg ritlecitinib

Association stronger with second versus first primary melanoma for having many moles at age 21 years, high genetic predisposition

More than twofold increased risk of prostate cancer seen for men with first melanoma diagnosed 10 to 15 years before study recruitment

Quality of life favored the pembrolizumab arm versus standard-of-care arm receiving ipilimumab, high-dose interferon α 2b

Of the types of emollient, emulsion was suggested as the better option for preventing infant atopic dermatitis development

Machine learning-based tool that predicts response to biologics significantly altered physician prescribing and improved patient outcomes